surgical treatment of brain metastases from lung cancer NARAYAN SUNDARESAN, M.D., JOSEPH H. GALIC1CH, M.D., AND EDWARD J. BEATTIE, JR., M.D.
|
|
- Alison Greer
- 5 years ago
- Views:
Transcription
1 J Neurosurg 58: , 1983 Surgical treatment of brain metastases from lung cancer NARAYAN SUNDARESAN, M.D., JOSEPH H. GALC1CH, M.D., AND EDWARD J. BEATTE, JR., M.D. Neurosurgery and Thoracic Services, Memorial Sloan-Kettering Cancer Center, New York, New York v t Thirty-five patients underwent surgical resection of brain metastases from non-oat-ceu lung cancer between 1978 and Twenty-nine patients received postoperative radiation therapy to the brain. Twenty-three patients were male and 12 were female. ntracranial metastases occurred as the initial symptom of malignancy in 14 patients, and at varying periods following treatment of the primary tumor in 21 patients. The primary tumor and involved nodes were treated by definitive surgery in 18 patients, palliative resection and interstitial radiation in 1 patients, and by radiation therapy or chemotherapy alone in seven patients. The overall median survival time was 14 months. Favorable prognostic variables included: 1) absence of local or systemic disease at time of craniotomy (median 23 months survival time); 2) aggressive treatment of the primary tumor (median 18 months survival time); and 3) metachronous onset of brain metastases (median 15 months survival time). These survival data represent a considerable improvement over the historical 6 months median period of survival in such patients. KEY WORDS 9 brain metastasis lung carcinoma 9 surgical treatment 9 metastatic tumor L UNG cancer is the leading cause of cancer deaths in men today. Recent data suggest a disproportionate rising incidence in women, and if this trend continues, it may outrank breast cancer as the leading neoplasm. 14 Approximately 135, cases are diagnosed annually in the United States alone, with 5-year survival rates of approximately 1%. 2 This poor survival rate is attributed to two factors: failure to diagnose the disease early enough for it to be potentially curable by surgery, and the failure of current systemic therapy to control disseminated disease.l,13,a7 Brain metastases represent the most important form of systemic relapse in lung cancer; estimates for the frequency of this complication vary from 18% to 57%. 6,7,22 The proclivity for brain metastases varies with histological type. Excluding oat-cell carcinoma, there is a much higher incidence in adenocarcinoma and large-cell undifferentiated carcinoma as compared to squamous carcinoma. 6 At this institution, approximately 2% of lung cancer patients develop brain metastases, many within the 1st year after diagnosis of the primary tumor. n patients with a single brain metastasis, surgical resection followed by irradiation is an important ther- apeutic option. 9,1~176 Historically, the median survival time of such patients, including those with lung cancer, has been 6 months or less. ~ n a previous report, we noted that the major determinant of survival in these patients was the extent of systemic metastasis, ai Furthermore, patients with lung cancer are particularly likely to have persistence of active disease in the chest at the time brain metastases become manifest. Recent improvements in treatment of the primary tumor have, however, been brought about by aggressive surgery alone, or in combination with brachytherapy. 15 t is now possible to achieve "local control" in up to 7% of operable patients, compared to about 5% in the past (B Hilaris, unpublished data). These results should be reflected in the longer survival of those patients who suffer relapse in a form for which effective treatment exists, such as solitary brain metastasis. n addition, during the same time period, refinements in computerized tomography (CT) have allowed more accurate and perhaps earlier detection of patients with single brain metastases. For these reasons, we have analyzed the results of surgical treatment of brain metastases from lung cancer within the past 4 years at the Memorial Sloan- Kettering Cancer Center. 666 J. Neurosurg. / Volume 58 / May, 1983
2 Surgical treatment of metastatic lung cancer Clinical Material From January, 1978, through September, 1981, 35 patients with brain metastases from non-oat-cell carcinoma of the lung underwent craniotomy by two of us (N.S. and J.H.G.) at this institution. Thirty-four of these patients had a single metastasis demonstrated by CT; one patient had two brain metastases. Twentythree patients were male, and 12 were female. Their ages ranged from 34 to 67 years (median 51 years). The histology of the primary tumor was adenocarcinoma in 29 patients, squamous cell carcinoma in five patients, and bronchiolar carcinoma in one patient. n 14 patients, the onset of brain metastases was synchronous (that is, these patients presented with brain metastases as the initial manifestation of cancer), and in 21 patients metachronous (that is, brain metastases occurred at varying periods following treatment of the primary tumor). The median duration of the interval between diagnosis of the primary tumor and diagnosis of the brain metastasis was 4 months (range to 48 months) for the entire series. f only patients with metachronous onset of brain metastases are considered, the median duration of this interval was 1 months. The primary lung tumor was treated by surgery (lobectomy and pneumonectomy) alone in 18 patients; 1 patients underwent palliative resection with radioactive implants (iridium- 192), and seven patients had no surgical treatment of the primary tumor. n those patients who underwent thoracotomy, the lung tumors were staged using the TNM system of the American Joint Committee for Cancer Staging. and End Results Reporting? The extent of systemic disease was evaluated in all patients by chest x-ray films and radionuclide bone and liver scans. Twenty-one patients had disease limited to the brain. Fourteen patients had persistent active tumor in the chest, and, of these, six also had metastases to bone and one had liver metastases. Thirty-two patients underwent elective craniotomy. n these patients, corticosteroid therapy was begun at least 3 days prior to surgery and all had localizing CT scans. 9 These preoperative measures were not carried out in three patients who underwent emergency craniotomy. Five tumors presented on the surface of the brain of which four involved the overlying dura, and 3 tumors were subcortical. A standard surgical technique was used. 9 n every patient, all tumor identifiable with x 4.5-power loupes was removed. Whenever feasible (in 18 cases), the tumor was removed as a single specimen. Postoperatively, 29 patients received radiation therapy. Whole-brain irradiation was given in 26, and focal irradiation to the tumor bed in three. Treatment with corticosteroids was maintained during postoperative radiation therapy, then tapered and successfully stopped in all 29 patients. Five patients were operated on after radiation therapy had failed to stem the disease, and one patient died without receiving irradiation. Two of these patients were successfully 1,.875 ~ 35 patients - 13 alive.zs.>_ O. o o =. i i i t J t i t T FG.. Overall survival time in 35 patients undergoing craniotomy for brain metastases from lung cancer between 1978 and weaned off steroids. Follow-up review with serial CT scans was carried out in 33 patients. Survival data were calculated using the life-table method. Factors evaluated for prognostic significance included: 1) the extent of resection of the primary tumor; 2) the nodal status at thoracotomy; 3) the presence of recurrent disease in the chest or extracranial metastases at time of craniotomy; and 4) the time of onset of brain metastases. Comparisons between subgroups were performed with the Wilcoxon and Mantel-Cox tests? Preoperative and postoperative neurological status was evaluated by means of the Karnofsky scale. We further estimated time from operation to neurological progression, using the lifetable method. For this index, all patients who developed neurological symptoms due to recurrent tumor, or for other reasons, were considered "deaths." Deaths occurring while the patient was experiencing stable neurological function were censored. Results One patient died of pulmonary embolus in the postoperative period, giving a mortality of 3%. Two patients developed postoperative clots, with subsequent uneventful courses after evacuation. Three patients had increased neurological deficits postoperatively. n two of these patients, one with a parietal lobe syndrome and another with aphasia and hemiparesis, the deficits improved to the point that they were both able to return to work. A third patient who developed dysphasia and hemiparesis recovered completely. All but three patients were weaned off steroids within 6 weeks posttreatment. These three patients were among the group in which radiation therapy had failed, and they had required chronic use of corticosteroids preoperatively. The survival data are shown in Figs. 1 through 6. The overall median period of survival was 14 months J. Neurosurg. / Volume 58 / May,
3 N. Sundaresan, J. H. Galicich and E. J. Beattie, Jr ~"Q-1 b- 1.,875 " ~ ~ 9 Patients- N O ~",75(.m,625 ll,-,5 r,375: a...25 'i t-,75 > ; L-.625 U} =,5 -~ 375 Q. ~-.z5 u-" J ~6Patients-N 1,~ J ~ -,.. 14 Patients - N 2.-,,--,-, o--o 6 Po!'*.'.'. 325, i J i L J t i i i i i i i i FG. 2. Period of survival by treatment of primary tumor. Curative resection was achieved in 18 patients (black circles), with a median survival time of 18 months; 1 patients had resection and radioactive implant (open circles), with a median survival time of 15 months; seven patients had no resection of the primary tumor (triangles), with a median survival time of 2 89 months. Thus, an untreated primary tumor was associated with significantly poor survival (p <.1). (Fig. 1). The overall 1-year survival rate was 53%, and the 2-year survival rate was 25%. Factors associated with a longer survival time included aggressive surgical treatment of the primary tumor (median survival time 15 to 18 months, Fig. 2); detectable disease limited to the brain only (median survival time 23 months, Fig. 3), and metachronous onset of metastases l,o,875 c.,75 E >,67-5 =, Q. ~_.25o, -Q-t- ~-..Q-O -- ~ -D -Q P-1- ] i FG. 3. Period of survival by extent of the disease. Of the 35 patients, 21 had negative bone scans and no local disease (black circles), with a median survival time of 23 months, and 14 had positive bone or liver scans or local disease (open circles), with a survival time of 5 months. Thus, the presence of local disease with positive bone/liver scans was associated with poor prognosis (p <.1).. t i J i J i J i i i i J i i J FG. 4. Period of survival by nodal status at thoracotamy. No denotes no involvement of nodes; N1 indicates positive findings at the hilar, interlobar, lobar, or parenchymal nodes; N2 indicates positive findings at the superior mediastinal, aortic, or inferior mediastinal nodes. Six unclassified patients had no surgical staging because they did not undergo thoracotomy. (median survival time 15 months, Fig. 5). Unfavorable factors included untreated primary tumor (median survival time 2 89 months, Fig. 2), and the presence of recurrent lung tumor or systemic metastases at the time of craniotomy (median survival time 5 months, Fig. 3). We were unable to demonstrate any significant association between nodal status and length of survival (Fig. 4). Only three patients (1%) had CT evidence of recurrence at the site of the original brain metastasis. 1,.875 =~.75._ ~>,625i tip,-.5 O ~),375 O..25o,125 -i b ~-~ a J. "i-~1o_, (~-t, i e--e 14 Patients- Synchronous (Median = 8,5 months) o---o 21 Patients-Metachronous (Median = 15 months) FG. 5. Period of survival by time of onset of the metastases. Synchronous onset was associated with shorter median survival, but the difference was not statistically significant. 668 J. Neurosurg. / Volume 58/May, 1983
4 Surgical treatment of metastatic lung cancer 1.,875 a~ e <>-- 8 Patients (Median = 19 mos.) E Patients - ~ Neurolocjically improved or stable 9,625 =,5,375. ~..25, i t i t t t t t i i t i FG. 6. Period of survival in a subset of eight patients with synchronous presentation of lung carcinoma and metastases to the brain, who underwent craniotomy followed by thoracotomy at this institution. g 625 o.5 o.375 _~.z5 8.lzs.~ FG. 7. Time to neurological progression: actuarial estimate of neurological palliation (see text). "Deaths" included surgical complication in four, radiation necrosis in one, cerebrovascular accident in one, status epilepticus due to chemotherapy in one, and central nervous system recurrence in eight. Reoperation in one of these patients resulted in wound infection and meningitis. Four patients developed a second intracranial metastasis distant from the primary site; two underwent repeat surgery, and two received additional radiation therapy. One patient in this group became dysphasic following reoperation. Two other patients developed carcinomatous meningitis. Radiation-related complications were found in two patients: radiation necrosis with hemiparesis in one, and ataxia and hydrocephalus in the other. Three patients developed deafness due to nerve dysfunction (two complete, and one partial), presumably from the combination of radiation and chemotherapy. Eight patients showed CT evidence of hydrocephalus and white matter attenuation, most likely from radiationinduced leukoencephalopathy, but they were clinically asymptomatic. Table 1 shows the functional status of the patients as assessed by the Karnofsky scale approximately 1 month after craniotomy as compared to that before operation. Calculated by actuarial methods, Fig. 7 shows that 75% of patients were improved or neurologically stable for 6 months or more, and that 65% retained improvement for 14 months. tween 1978 and 198 as compared to less than 1% in two other series, lz,z3 Tables 2 and 3 compare other important patient parameters between the present series and the patients operated on between 1972 and The more recent group of patients were in better neurological condition, and fewer had systemic metastases, but a greater proportion had early onset of brain metastases (Table 2). Of unknown but indeterminable significance is the role of CT scanning in detecting truly single brain metastases at an earlier date in the present series, and the fact that bone and liver/spleen scans were not routinely used for determining extent of disease in the earlier group. Although surgical treatment of the primary tumor appears comparable in the two groups, as noted previously, recent advances evaluated in a larger group of patients have resulted in better local control. 15,]7,~8 n addition, five out of 15 patients who received chemotherapy displayed either partial or complete regression of systemic tumor. While both of these factors may have played a role in improved survival, their impact in this small series is impossible to gauge. Discussion The survival data presented here represent a considerable improvement over previous surgical series reported from this and other institutions, l~176 Among the possible explanations for this improvement must be included 1) better patient selection; 2) improved treatment of the primary tumor and systemic metastases; and 3) improved treatment of the intracranial tumor. At this institution, 13% of patients with brain metastases from lung cancer underwent craniotomy be- TABLE 1 Comparison of pre- and postoperative functional status Preoperative No. of Postoperative Status Karnofsky Cases Score mproved Stable Worse l " total cases * This patient died 2 weeks postoperatively. J. Neurosurg. / Volume 58 / May,
5 N. Sundaresan, J. H. Galicich and E. J. Beattie, Jr. TABLE 2 Comparison of patients operated on (Group A), with those operated on (Group B) Group A Group B Parameters No. Percent No. Percent clinical presentation synchronous onset metastasis < 1 yr after pri mary neurological grade Grade 1 (minimal or no deficit) Grade 2 (moderate deficit) Grade 3 (severe neurologi cal deficit) extent of disease intracranial lesion only local or systemic disease present unknown 1 3 surgical treatment of primary tumor none implant resected total cases t is quite evident that the major difference between the two series is the increased survival time of patients with disease limited to the brain (Table 3), and that a substantial proportion of the improvement occurred after treatment of the brain metastases. n this regard, precise localization of the intracranial tumor by CT scanning has recently allowed removal of very small subcortical tumors as well as complete gross resection of larger neoplasms, with minimal morbidity. Despite the fact that several different irradiation protocols were used following surgery in the two groups, recent data showed no substantial difference in the effectiveness of varying dose-fractionations used for wholebrain radiation therapy, lz Aside from period of survival, another important consideration is the quality of neurological palliation provided by surgery. Table 1 shows that 75% of our patients improved or maintained their neurological status following surgery. More recently, the Radiation Therapy Oncology Group introduced two further indices to evaluate neurological palliation22 These included "time to neurological progression," and the proportion of patients who were neurologically symptom-free until death. n comparison with results reported in that pooled study, the surgically treated patients in our series showed a greater period of relief from neurological symptoms, and a larger proportion of these patients maintained this improvement until death (Fig. 7). Additionally, all but three patients were weaned off steroids posttreatment, thus avoiding the complications of long-term steroid therapy? An important clinical problem on which the present data bear is the management of a patient presenting TABLE 3 Survival data of patients operated on (Group A), compared to those operated on (Group B) Survival Data Group A Group B overall survival (from diagnosis of cancer) median (mos) yr (%) yrs (%) 26 4 brain metastasis median (mos) yr (%) yrs (%) 5 25 intracranial disease only median (mos) yr (%) yrs (%) 11 5 extracranial disease present median (mos) yr (%) 15 2 yrs (%) with a solitary cerebral neoplasm, and who is discovered to have a possible primary lesion in the lung on chest x-ray film. Although our data suggest that synchronous onset of metastases carries a poorer prognosis, our series includes five patients in whom the primary lesion was considered inadequately treated at another institution. n a subset of eight patients (Fig. 6) who underwent craniotomy followed by thoracotomy at this institution, the median survival time exceeded 1 year. Only the three patients who were found to have unresectable mediastinal nodes at thoracotomy died within the 1st year. We believe, therefore, that an aggressive therapeutic approach is indicated in patients who present with synchronous onset of metastases, if the lung lesion is deemed resectable. Tissue diagnosis by needle biopsy of the lung prior to surgery is important to exclude oat-cell carcinoma. Although the prognostic variables identified in this and other series 19,21 are helpful in selecting patients who might best benefit from resection of an intracranial metastasis, other considerations must be given weight. 1~ Patients who deteriorate acutely from intracranial hemorrhage, or who are otherwise symptomatic from a large mass lesion can often receive neurological palliation by resection of the intracranial mass, even though the ultimate prospects for longterm survival appear poor. n addition, as more effective systemic treatment for lung cancer becomes available, the pool of patients who are candidates for surgical removal of solitary brain metastases should increase. Acknowledgment We would like to thank Basil Hilaris, M.D., Chief, Brachytherapy Service, Memorial Sloan-Kettering Cancer Center, for providing helpful criticism and clinical data relevant to this paper. 67 J. Neurosurg. / Volume 58 / May, 1983
6 Surgical treatment of metastatic lung cancer References 1. Aisner J, Hansen HH: Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65: , American Cancer Society: CA--A Cancer Journal for Clinicians. Cancer Statistics, New York: American Cancer Society, American Joint Committee for Cancer Staging and End Results Reporting: Manual for Staging of Cancer, Chicago: American Joint Committee, 1977, pp Axelrod L: Glucocorticoid therapy. Medicine 55:39-65, Cairncross JG, Posner JB: Management of brain metastases, in Walker MD (ed): Oncology of the Nervous System. The Hague, The Netherlands: Martinus Nijhoff (n press) 6. Cox JD, Eisert DR, Komaki R, et al: Patterns of failure following treatment of apparently localized carcinoma of the lung, in Muggia FM, Rozencweig M (eds): Lung Cancer: Progress in Therapeutic Research. New York: Raven Press, 1979, 1p Cox JD, Stanley K, Petrovich Z, et al: Cranial irradiation in cancer of the lung of all cell types. JAMA 245: , Dixon WJ, Brown MB (eds): BMDP-79: Biomedical Computer Programs, P-Series. Berkeley, Cal: University of California Press, Galicich JH: Surgery of malignant brain tumors, in Vick N (ed): Seminars in Neurology, Vol 1. New York: Thieme-Stratton, 1981, pp Galicich JH, Sundaresan N, Arbit E, et al: Surgical treatment of single brain metastasis: factors associated with survival. Cancer 45: , Galicich JH, Sundaresan N, Thaler HT: Surgical treatment of single brain metastasis. Evaluation of results by computerized tomography scanning. J Neurosurg 53: 63-67, Gelber RD, Larson M, Borgelt BB, et al: Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 48: , Gralla RJ, Casper ES, Kelsen DP, et al: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann ntern Med 95:414-42, Greenwald P, Polan AK: Lung-cancer deaths among women. N Engl J Med 31:274, 1979 (Letter) 15. Hilaris BS, Martini N: nterstitial brachytherapy in cancer of the lung: a 2 year experience. nt J Radiat Oncol Biol Phys 5: , Magilligan DJ Jr, Rogers JS, Knighton RS, et al: Pulmonary neoplasm with solitary cerebral metastasis. Resuits of combined excision. J Thorac Cardiovasc Surg 72:69-698, Martini N: dentification and prognostic implications of mediastinal lymph node metastases in carcinoma of the lung, in Muggia FM, Rozencweig M (eds): Lung Cancer: Progress in Therapeutic Research. New York: Raven Press, 1979, pp Martini N, Flehinger B J, Zaman MB, et al: Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 8:39-399, Robin E, Bitran JD, Golomb HM, et al: Do all patients with non-small cell lung cancer and brain metastases have a limited survival. Proc ASCO 22:57, 1981 (Abstract) 2. Salerno TA, Munro DD, Little JR: Surgical treatment of bronchogenic carcinoma with a brain metastasis. J Neurosurg 48:35-354, Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. JNC 65:25-32, Tomlinson BE, Perry RH, Stewart-Wynne EG: nfluence of site of origin of lung carcinomas on clinical presentation and central nervous system metastases. J Neurol Neurosurg Psychiatry 42:82-88, West J, Maor M: ntracranial metastases: behavioral patterns related to primary site and results of treatment by whole brain irradiation. nt J Radiat Oncol Bioi Phys 6:11-15, Winston KR, Walsh JW, Fischer EG: Results of operative treatment of intracranial metastatic tumors. Cancer 45: , 198 Manuscript received September 24, Address reprint requests to: Narayan Sundaresan, M.D, Neurosurgery Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 121. J. Neurosurg. / Volume 58 / May,
B bidity in cancer patients. Recent data suggest that
Surgical Treatment of Brain Metastases Clinical and Computerized Tomography Evaluation of the Results of Treatment NARAYAN SUNDARESAN, MD, AND JOSEPH H. GALICICH, MD The results of treatment of brain metastases
More informationSurgical treatment of multiple brain metastases
J Neurosurg 79:210-216, 1993 Surgical treatment of multiple brain metastases RAJESH K. BINDAL, B.A., RAYMOND SAWAYA, M.D., MILAM E. LEAVENS, M.D., ANO J. JACK LEE, PH.D. Departments of Neurosurgery and
More information24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons
Surgical Management of Lung Cancer with Solitary Cerebral Metastasis John R. Hankins, M.D., John E. Miller, M.D., Michael Salcman, M.D., Frank Ferraro, M.D., David C. Green, M.D., Safuh Attar, M.D., and
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationCauses of Treatment Failure and Death in Carcinoma of the Lung
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 54 (1981), 201-207 Causes of Treatment Failure and Death in Carcinoma of the Lung JAMES D. COX, M.D.,a AND RAYMOND A. YESNER, M.D.b The Medical College of Wisconsin,
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationInterstitial Irradiation for Unresectable Carcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 20 NUMBER 5 NOVEMBER 1975 Interstitial Irradiation for Unresectable Carcinoma
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationThe Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPrognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer
Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,
More informationSurgical treatment of primary lung cancer with synchronous brain metastases
General Thoracic Surgery CHD GTS ACD GTS CSP TX Surgical treatment of primary lung cancer with synchronous brain metastases Peter S. Billing, MD Daniel L. Miller, MD Mark S. Allen, MD Claude Deschamps,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationKey words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery
Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases* Pierre Bonnette, MD; Philippe Puyo, MD; Christophe Gabriel, MD; Roger Giudicelli, MD; Jean-François Regnard, MD; Marc
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationSolitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
Original Report ISSN 1537-744X; DOI 10.1100/tsw.2004.39 Solitary Contralateral Adrenal after Nephrectomy for Renal Cell Carcinoma Nikolaos Antoniou, M.D. and Demetrios Karanastasis, M.D. General Hospital
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationLaboratory data from the 1970s first showed that malignant melanoma
2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationSignificance of Metastatic Disease
Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationsarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.
1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationTreatment of Inoperable Lung Carcinoma: A Combined Modality Approach
Treatment of Inoperable ung Carcinoma: A Combined Modality Approach Hiroshi Takita, M.D., Ariel C. Hollinshead, h.d., Donna J. Rizzo, R.N., Christine M. Kramer, M.S., Tah Y. Chen, M.D., Joginder N. Bhayana,
More informationSurgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28
NAOSITE: Nagasaki University's Ac Title Author(s) Surgical Treatment for Pulmonary Me Ayabe, Hiroyoshi; Tomita, Masao; Na Katsunobu; Nakao, Susumu; Eguchi, M Tsunehisa; Kugimiya, Toshiyasu Citation Acta
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationPrognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment q
European Journal of Cardio-thoracic Surgery 25 (2004) 1107 1113 www.elsevier.com/locate/ejcts Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationTumour size as a prognostic factor after resection of lung carcinoma
Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationStage III non small cell lung cancer and metachronous brain metastases
General Thoracic Surgery Stage III non small cell lung cancer and metachronous brain metastases Nader Moazami, MD a Thomas W. Rice, MD a Lisa A. Rybicki, MS b David J. Adelstein, MD c Sudish C. Murthy,
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationAggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn
Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Isadore Mandelbaum, M.D., Stephen D. Williams, M.D., and Lawrence H. Einhorn, M.D. ABSTRACT During the past
More informationHong-Gyun Wu, M.D., Charn Il Park, M.D., S ung Whan Ha, M.D., and Il Han Kim, M.D.
J. Korean Soc Ther Radiol Oncol 1999;17(1):108 112 1) S ign ifica nce of S uprac lav ic ula r Lymph Node Invo lve me nt o n Dete rm inat io n of Clin ica l Stag ing fo r Tho rac ic Es o phagea l Ca rc
More informationChemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma
Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma of the Lung Scott L. Faulkner, M.D., R. Benton Adkins, Jr., M.D., and Vernon H. Reynolds, M.D. ABSTRACT Ten patients with inoperable or recurrent
More informationHarrington rod stabilization for pathological fractures of the spine NARAYAN SUNDARESAN, M.D., JOSEPH H. GALICICH, M.D., AND JOSEPH M. LANE, M.D.
J Neurosurg 60:282-286, 1984 Harrington rod stabilization for pathological fractures of the spine NARAYAN SUNDARESAN, M.D., JOSEPH H. GALICICH, M.D., AND JOSEPH M. LANE, M.D. Neurosurgery and Orthopedic
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationSECONDARIES: A PRELIMINARY REPORT
HPB Surgery, 1990, Vol. 2, pp. 69-72 Reprints available directly from the publisher Photocopying permitted by license only 1990 Harwood Academic Publishers GmbH Printed in the United Kingdom CASE REPORTS
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationBrain Metastasis in Resected Lung Cancer: Value of Intensive Follow-up With Computed Tomography
Brain Metastasis in Resected Lung Cancer: Value of Intensive Follow-up With Computed Tomography Kohei Yokoi, MD, Naoto Miyazawa, MD, and Toshimoto rai, MD Divisions of Thoracic Surgery and Neurosurgery,
More informationManagement of single brain metastasis: a practice guideline
PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationSurgical Approaches to Pulmonary Metastases
Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationResection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer
Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationAdrenal glands are a common metastatic site for non small cell lung cancer
Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationOutcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases
ORIGIL ARTICLE Brain Tumor Res Treat 2013;1:64-70 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer
More informationHong Kong Hospital Authority Convention 2018
Hong Kong Hospital Authority Convention 2018 Stereotactic Radiosurgery in Brain Metastases - Development of the New Treatment Paradigm in HA, Patients Profiles and Their Clinical Outcomes 8 May 2018 Dr
More informationBrain metastases: changing visions
Brain metastases: changing visions Roberto Spiegelmann, MD Baiona, 2014 Head, Stereotactic Radiosurgery Unit Dept of Neurosurgery, Chaim Sheba Medical Center Tel Hashomer, Israel The best current estimate
More informationLung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationSurgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital
Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition
More informationThe single supratentorial lesion. An evaluation of preoperative diagnostic tests
J Neurosurg 53:364-368, 1980 The single supratentorial lesion An evaluation of preoperative diagnostic tests RAND M. VOORHIES, M.D., NARAYAN SUNDARESAN, M.D., AND H. Tzvl THALER, PH.D. Department of Neurosurgery,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationEfficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas
J Neurosurg 93:201 207, 2000 Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas EVANTHIA GALANIS, M.D., JAN
More informationRelevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François
More informationIntraoperative Radiation Therapy for
Frontiers ofradiation Therapy and Oncology Reprint Editors: J.M. Vaeth, J.L. Meyer, San Francisco, Calif. ~' Publishers: S.Karger, Basel Printed in Switzerland Vaeth JM, Meyer JL (eds): The Role of High
More informationWorkup of a Solid Liver Lesion
Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More information